Thomas W LeBlanc1, Ryan D Nipp2, Christel N Rushing3, Greg P Samsa3, Susan C Locke3, Arif H Kamal4, David F Cella5, Amy P Abernethy6. 1. Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA; Center for Learning Health Care, Duke Clinical Research Institute, Durham, North Carolina, USA; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. 2. Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 3. Center for Learning Health Care, Duke Clinical Research Institute, Durham, North Carolina, USA. 4. Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA; Center for Learning Health Care, Duke Clinical Research Institute, Durham, North Carolina, USA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. 5. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 6. Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA; Center for Learning Health Care, Duke Clinical Research Institute, Durham, North Carolina, USA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: amy.abernethy@duke.edu.
Abstract
CONTEXT: The cancer anorexia-cachexia syndrome (CACS) is common in patients with advanced solid tumors and is associated with adverse outcomes including poor quality of life (QOL), impaired functioning, and shortened survival. OBJECTIVES: To apply the recently posed weight-based international consensus CACS definition to a population of patients with advanced non-small cell lung cancer (NSCLC) and explore its impact on patient-reported outcomes. METHODS: Ninety-nine patients participated in up to four study visits over a six-month period. Longitudinal assessments included measures of physical function, QOL, and other clinical variables such as weight and survival. RESULTS: Patients meeting the consensus CACS criteria at Visit 1 had a significantly shorter median survival (239.5 vs. 446 days; hazard ratio, 2.06, P < 0.05). Physical function was worse in the CACS group (mean Karnofsky Performance Status score 68 vs. 77, Eastern Cooperative Oncology Group Performance Status score 1.8 vs. 1.3, P < 0.05 for both), as was QOL (Functional Assessment of Cancer Therapy-General [FACT-G] Lung Cancer subscale of 17.2 vs. 19.9, Anorexia/Cachexia subscale of 31.4 vs. 37.9, P < 0.05 for both). Differences in the FACT-G and the Functional Assessment of Chronic Illness Therapy-Fatigue subscale approached but did not reach statistical significance. Longitudinally, all measures of physical function and QOL worsened regardless of CACS status, but the rate of decline was more rapid in the CACS group. CONCLUSION: The weight-based component of the recently proposed international consensus CACS definition is useful in identifying patients with advanced NSCLC who are likely to have significantly inferior survival and who will develop more precipitous declines in physical function and QOL. This definition may be useful for clinical screening purposes and identify patients with high palliative care needs.
CONTEXT: The cancer anorexia-cachexia syndrome (CACS) is common in patients with advanced solid tumors and is associated with adverse outcomes including poor quality of life (QOL), impaired functioning, and shortened survival. OBJECTIVES: To apply the recently posed weight-based international consensus CACS definition to a population of patients with advanced non-small cell lung cancer (NSCLC) and explore its impact on patient-reported outcomes. METHODS: Ninety-nine patients participated in up to four study visits over a six-month period. Longitudinal assessments included measures of physical function, QOL, and other clinical variables such as weight and survival. RESULTS:Patients meeting the consensus CACS criteria at Visit 1 had a significantly shorter median survival (239.5 vs. 446 days; hazard ratio, 2.06, P < 0.05). Physical function was worse in the CACS group (mean Karnofsky Performance Status score 68 vs. 77, Eastern Cooperative Oncology Group Performance Status score 1.8 vs. 1.3, P < 0.05 for both), as was QOL (Functional Assessment of Cancer Therapy-General [FACT-G] Lung Cancer subscale of 17.2 vs. 19.9, Anorexia/Cachexia subscale of 31.4 vs. 37.9, P < 0.05 for both). Differences in the FACT-G and the Functional Assessment of Chronic Illness Therapy-Fatigue subscale approached but did not reach statistical significance. Longitudinally, all measures of physical function and QOL worsened regardless of CACS status, but the rate of decline was more rapid in the CACS group. CONCLUSION: The weight-based component of the recently proposed international consensus CACS definition is useful in identifying patients with advanced NSCLC who are likely to have significantly inferior survival and who will develop more precipitous declines in physical function and QOL. This definition may be useful for clinical screening purposes and identify patients with high palliative care needs.
Authors: Thomas W LeBlanc; Greg P Samsa; Steven P Wolf; Susan C Locke; David F Cella; Amy P Abernethy Journal: Support Care Cancer Date: 2015-01-14 Impact factor: 3.603
Authors: Kathryn Elizabeth Hudson; Steven Paul Wolf; Gregory P Samsa; Arif H Kamal; Amy Pickar Abernethy; Thomas William LeBlanc Journal: J Palliat Med Date: 2018-02-08 Impact factor: 2.947
Authors: Bhavani S Gannavarapu; Steven K M Lau; Kristen Carter; Nathan A Cannon; Ang Gao; Chul Ahn; Jeffrey J Meyer; David J Sher; Aminah Jatoi; Rodney Infante; Puneeth Iyengar Journal: J Oncol Pract Date: 2018-02-21 Impact factor: 3.840
Authors: Nicole E Rich; Samuel Phen; Nirali Desai; Sukul Mittal; Adam C Yopp; Ju Dong Yang; Jorge A Marrero; Puneeth Iyengar; Rodney E Infante; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2021-09-20 Impact factor: 13.576
Authors: Antonio Jose Grande; Valter Silva; Larissa Sawaris Neto; João Pedro Teixeira Basmage; Maria S Peccin; Matthew Maddocks Journal: Cochrane Database Syst Rev Date: 2021-03-18